

PROTEOMICS: TECHNOLOGIES AND GLOBAL MARKETS



BIO034D
February 2015

John Bergin
Project Analyst

ISBN: 1-62296-046-7



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE	3
SCOPE AND FORMAT	3
METHODOLOGY	3
INFORMATION SOURCES	4
RELATED BCC RESEARCH REPORTS	4
ANALYST'S CREDENTIALS	4
BCC RESEARCH ONLINE SERVICES	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY, 2013-2019 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	11
PROTEOMIC TECHNOLOGIES	11
<i>TABLE 1 ARRAY VERSUS LOAC BIOCHIPS</i>	12
SCOPE OF REPORT	13
<i>TABLE 2 SCOPE OF REPORT</i>	13
PROTEOMICS MARKET	13
<i>TABLE 3 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	14
DRIVING FORCES FOR PROTEOMICS INDUSTRY GROWTH	15
<i>TABLE 4 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES</i>	15
THE PROTEOMICS INDUSTRY	16
<i>TABLE 5 BIOCHIP INDUSTRY COMPARISONS</i>	16
CHAPTER 4 PROTEOMICS TECHNOLOGIES	18
INTRODUCTION TO TECHNOLOGY PLATFORMS	18
<i>FIGURE 1 MASS SPECTROMETRY GENERALIZED WORKFLOW SCHEMATIC</i>	18
<i>FIGURE 2 PROTEOMIC BIOCHIP AND ARRAY FORMATS</i>	19
MS-BASED PROTEOMICS TECHNOLOGIES	20
SAMPLE PREPARATION ASSAYS	20
TAGGING/AFFINITY METHODS	21
MS INSTRUMENTS AND CONSUMABLES	22
<i>TABLE 6 MASS SPECTROMETER PLATFORMS</i>	23
BIOCHIP-BASED PROTEOMICS TECHNOLOGIES	23
<i>TABLE 7 BIOCHIP-BASED PROTEOMIC TECHNOLOGIES</i>	23
<i>TABLE 8 PLANAR-BASED VERSUS BEAD-BASED ARRAYS</i>	24
MULTIPLEX PROTEOMICS SYSTEMS	25
<i>TABLE 9 ADVANTAGES OF MULTIPLEXING FOR DIAGNOSTICS</i>	25
PROTEOGENOMICS	27
RECENT ADVANCES IN PROTEOMIC TECHNOLOGIES	27

TOPIC	PAGE NO.
<i>TABLE 10 TECHNICAL ADVANCES IN PROTEOMICS</i>	28
CHAPTER 5 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	31
<i>TABLE 11 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT</i>	31
TARGET DISCOVERY	31
LEAD IDENTIFICATION	33
LEAD OPTIMIZATION	33
PRECLINICAL STUDIES	34
CHAPTER 6 PROTEOMICS SCIENTIFIC INITIATIVES	36
<i>TABLE 12 LARGE-SCALE PROTEOMIC INITIATIVES</i>	36
CHAPTER 7 CLINICAL PROTEOMICS APPLICATIONS	41
<i>TABLE 13 STRATEGIES FOR OVERCOMING HIGH-ABUNDANCE PROTEINS IN CLINICAL SAMPLES</i>	41
CANCER APPLICATIONS	42
CANCER OVERVIEW	42
<i>TABLE 14 ESTIMATED U.S. INCIDENCE AND DEATHS FOR SELECTED CANCERS, 2010 AND 2013</i>	42
Bladder Cancer	43
<i>TABLE 15 STATUS OF BLADDER CANCER NEXT GENERATION DIAGNOSTICS TESTS</i>	43
Breast Cancer	44
Breast Cancer Screening	44
Prognosis and Pharmacogenetics Tests	45
<i>TABLE 16 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION</i>	46
Breast Cancer MDx Platforms	46
<i>TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS</i>	47
Status of Next Generation Breast Cancer Tests	48
<i>TABLE 18 STATUS OF NEXT GENERATION BREAST CANCER TESTS</i>	48
Breast Cancer Early Detection/Screening Tests	50
Breast Cancer Risk Tests	51
Response to Chemotherapy; Recurrence Probability; Subtyping	52
Colorectal Cancer	55
Gastric Cancer	56
<i>TABLE 19 STATUS OF GASTRIC/STOMACH CANCER NEXT GENERATION DIAGNOSTICS TESTS</i>	57
Kidney Cancer	57
<i>TABLE 20 STATUS OF KIDNEY CANCER NEXT GENERATION DIAGNOSTICS TESTS</i>	58
Lung Cancer	59
<i>TABLE 21 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%)</i>	59
<i>TABLE 22 STATUS OF LUNG CANCER NEXT GENERATION DIAGNOSTICS TESTS</i>	60
Lymphomas	63
<i>TABLE 23 STATUS OF LYMPHOMA CANCER NEXT GENERATION DIAGNOSTICS TESTS</i>	63
Ovarian Cancer	64
<i>TABLE 24 EARLY SCREENING OVARIAN CANCER TESTS</i>	64
<i>TABLE 25 STATUS OF OVARIAN CANCER NEXT GENERATION DIAGNOSTICS TESTS</i>	66

TOPIC	PAGE NO.
Pan-Cancer	67
<i>TABLE 26 STATUS OF PAN-CANCER NEXT GENERATION DIAGNOSTICS TESTS</i>	68
Prostate Cancer	71
<i>TABLE 27 STATUS OF PROSTATE CANCER NEXT GENERATION DIAGNOSTICS TESTS</i>	72
Thyroid Cancer	75
<i>TABLE 28 STATUS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS</i>	75
INFECTIOUS DISEASES	77
DIABETES	77
NEUROLOGICAL DISORDERS	77
ALZHEIMER'S DISEASE	77
<i>TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES</i>	78
SCHIZOPHRENIA	79
IMMUNE DISEASES	81
HLA TYPING	81
AUTOIMMUNE DISEASE	81
<i>TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET</i>	82
CARDIOVASCULAR DISEASE	83
PREECLAMPSIA	83
<i>TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS</i>	83
CHAPTER 8 PROTEOMICS INDUSTRY	86
INDUSTRY ACQUISITIONS	86
<i>TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014</i>	86
INDUSTRY STRATEGIC ALLIANCES	89
<i>TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014</i>	89
MASS SPECTROMETRY INDUSTRY	99
<i>TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS</i>	100
<i>TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES</i>	101
<i>TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES</i>	103
CHROMATOGRAPHY INDUSTRY	103
<i>FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW</i>	104
<i>TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES</i>	104
<i>TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES</i>	105
PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY	106
<i>TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY</i>	106
PROTEOMICS BIOCHIP INDUSTRIES	108
PEPTIDE MICROARRAY INDUSTRY	108
<i>TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES</i>	108
HIGH DENSITY PROTEIN ARRAY INDUSTRY	109
<i>TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES</i>	109
ANTIBODY MICROARRAY INDUSTRY	110
<i>TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES</i>	110
CHINA'S BIOCHIP INDUSTRY	111
<i>TABLE 43 CHINA'S BIOCHIP INDUSTRY</i>	112
LOAC PROTEOMICS INDUSTRY	113
<i>TABLE 44 LOAC COMPETITOR LANDSCAPE</i>	114

TOPIC	PAGE NO.
CHEMICAL PROTEOMICS INDUSTRY	116
ANTIBODY REAGENT INDUSTRY	116
<i>TABLE 45 ANTIBODY REAGENT MARKET, 2014 (%)</i>	117
MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY	118
<i>TABLE 46 MULTIPLEX PROTEIN IN-VITRO DIAGNOSTICS COMPANIES</i>	118
DRIED BLOOD SPOTTING PROTEOMICS INDUSTRY	120
<i>TABLE 47 DRIED BLOOD SPOT PROTEOMICS INDUSTRY</i>	121
SINGLE CELL PROTEOMICS INDUSTRY	122
<i>TABLE 48 SINGLE CELL PROTEOMICS INDUSTRY</i>	122
CHAPTER 9 PROTEOMICS MARKETS	125
DRIVING FORCES OF PROTEOMICS INDUSTRY GROWTH	125
<i>TABLE 49 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES</i>	125
GLOBAL PROTEOMICS MARKETS	126
MARKET SUMMARY	126
<i>TABLE 50 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2019 (\$ MILLIONS)</i>	127
RESEARCH MARKET	129
<i>TABLE 51 GLOBAL PROTEOMIC RESEARCH MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	129
<i>TABLE 52 GLOBAL PROTEOMIC RESEARCH MARKET BY BIOCHIP PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	130
DRUG DISCOVERY AND DEVELOPMENT MARKETS	130
<i>TABLE 53 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT PRODUCT MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	130
<i>TABLE 54 GLOBAL PROTEOMIC BIOCHIP DRUG DISCOVERY AND DEVELOPMENT MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	131
PROTEOMICS DIAGNOSTIC MARKET	132
<i>TABLE 55 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	132
<i>TABLE 56 GLOBAL BIOCHIP DIAGNOSTIC MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	133
<i>TABLE 57 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY DISEASE TYPE, THROUGH 2019 (\$ MILLIONS)</i>	135
<i>TABLE 58 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR DIABETES, NEUROLOGICAL, AUTOIMMUNE, INFECTIOUS DISEASE, HLA TYPING, AND CARDIOVASCULAR DISEASE APPLICATIONS</i>	136
<i>TABLE 59 SEPSIS DIAGNOSTICS INDUSTRY</i>	137
<i>TABLE 60 GLOBAL PROTEOMIC CANCER DIAGNOSTIC PRODUCT MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	139
MASS SPECTROMETRY-BASED PROTEOMIC MARKET	142
<i>TABLE 61 GLOBAL MASS SPECTROMETRY MARKET BY PRODUCT TYPE, THROUGH 2019 (\$ MILLIONS)</i>	142
<i>TABLE 62 GLOBAL MASS SPECTROMETRY MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)</i>	143
MS-Based Clinical Diagnostics Markets	144
MS Clinical Platforms	145
<i>TABLE 63 MRM-MS VERSUS MALDI MS IN CLINICAL APPLICATIONS</i>	145
<i>TABLE 64 MS CLINICAL INDUSTRY</i>	146
<i>TABLE 65 PHOSPHOPROTEOMICS PLATFORMS FOR CANCER APPLICATIONS</i>	148

TOPIC	PAGE NO.
<i>TABLE 66 GLOBAL MASS SPECTROMETRY INSTRUMENT PROTEOMICS MARKET BY TECHNIQUE, THROUGH 2019 (\$ MILLIONS)</i>	149
<i>TABLE 67 GLOBAL MASS SPECTROMETRY CONSUMABLE MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	150
BIOCHIP-BASED PROTEOMICS MARKET	151
<i>TABLE 68 GLOBAL PROTEOMIC BIOCHIP MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	151
<i>TABLE 69 GLOBAL PROTEOMIC ARRAY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	152
<i>TABLE 70 GLOBAL PROTEOMIC BIOCHIP MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)</i>	153
<i>TABLE 71 GLOBAL PROTEOMIC ARRAY MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)</i>	154
<i>TABLE 72 GLOBAL PROTEOMIC LOAC MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)</i>	156
PROTEOMICS GEOGRAPHIC MARKET	158
<i>TABLE 73 GLOBAL PROTEOMIC MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	158
<i>TABLE 74 GLOBAL PROTEOMIC DIAGNOSTIC MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	159
CHAPTER 10 PROTEOMICS PATENTS	162
BIOCHIP PATENTS	162
PROTEIN ARRAY PATENTS	162
<i>TABLE 75 ARRAY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014</i>	162
LAB-ON-A-CHIP PATENTS	163
<i>TABLE 76 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014</i>	163
MASS SPECTROMETRY PATENTS	163
<i>TABLE 77 MASS SPECTROMETRY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014 (NO. OF PATENTS)</i>	164
CHAPTER 11 COMPANY PROFILES	166
ABCODIA LTD.	166
ABLYNX NV	166
ACTIVIOMICS LTD.	167
ACTIVX BIOSCIENCES INC.	167
ADVANCED PROTEOME THERAPEUTICS INC.	168
AGILENT TECHNOLOGIES INC.	168
APPLIED MICROARRAYS	169
APPLIED PROTEOMICS	170
ARRAYIT CORP.	171
ASTUTE MEDICAL INC.	172
AVACTA GROUP PLC	173
AYOXXA BIOSYSTEMS GMBH	174
BIOCARTIS NV	174
BIODESIX INC.	175
BIOGNOSYS AG	176
BIOMERIEUX SA	177
BIOPROXIMITY LLC	177
BIO-RAD LABORATORIES INC.	178

TOPIC	PAGE NO.
BIO-TECHNE INC.	178
BRUKER CORP.	179
CAMBRIDGE PROTEIN ARRAYS LTD.	180
CAPRION PROTEOME INC.	181
CAPROTEC BIOANALYTICS GMBH	181
CARMENTA BIOSCIENCE INC.	182
CDI LABORATORIES INC.	182
CRELUX GMBH	182
CRESCENDO BIOSCIENCE	183
CRYSTALGENOMICS INC.	184
CYVEK INC.	184
DANAHER CORP.	185
DIASSESS	186
DIGILAB INC.	187
EPICYPHER INC.	187
EVOTEC AG	187
FLUIDIGM CORP	189
GENERAL ELECTRIC CO.	189
GLAXOSMITHKLINE PLC	189
GLOBAL DISCOVERY BIOSCIENCES	190
GL SCIENCES INC.	191
HEALTHTELL INC.	191
HYBRIGENICS SA	191
<i>TABLE 78 APPLICATIONS FOR Y2H AND YCHEMH PROTEOMICS PLATFORMS</i>	192
IMMUNOVIA AB	193
IMTAKT CORP.	193
INTEGRATED DIAGNOSTICS	193
INDI MOLECULAR	194
IRIS INTERNATIONAL INC.	195
LABCYTE INC.	195
LEAP TECHNOLOGIES INC.	196
LUMINEX CORP.	196
MERCK & CO. INC.	197
MERCK KGAA	197
MICROLYTIC	198
MRM PROTEOMICS INC.	198
MOSAIQUES DIAGNOSTICS AND THERAPEUTICS AG	199
MYCARTIS	199
MYRIAD GENETICS INC.	200
NEWOMICS INC.	201
NIRMIDAS BIOTECH INC.	202
OLINK BIOSCIENCE	202
ONCOPLEX DIAGNOSTICS	203
OPKO HEALTH INC.	203
PERKINELMER INC.	204
PERSONALIZED CANCER THERAPY INC.	205
PFIZER INC.	205

TOPIC	PAGE NO.
PHENOMENEX INC.	206
PHYLOGICA LTD.	206
PRESSURE BIOSCIENCES INC.	207
PROMETIC LIFE SCIENCES INC.	208
PROTAGEN AG	209
PROTEA BIOSCIENCES INC.	209
PROTEOCYTE DIAGNOSTICS INC.	211
PROTEOGENIX	211
PROTEOME SCIENCES PLC	211
PROTEOMICS INTERNATIONAL PTY LTD	212
PROTEOVISTA LLC	213
PROVISTA DIAGNOSTICS INC.	213
QIAGEN NV	214
QUANSYS BIOSCIENCES	215
QUANTERIX INC.	215
QUEST DIAGNOSTICS INC.	216
REPLIGEN CORP.	217
RETROGENIX LTD.	217
SAMDI TECH INC.	218
SERA PROGNOSTICS	218
SHIMADZU CORP.	219
SHISEIDO COMPANY LTD.	219
SHOWA DENKO KK	220
SIGMA ALDRICH	220
SINGULEX INC.	221
SISCAPA ASSAY TECHNOLOGIES INC.	221
SOMALOGIC INC.	222
<i>TABLE 79 SOMALOGIC PROTEOMIC METHODS</i>	223
SPHERE FLUIDICS LTD.	223
SPOTON CLINICAL DIAGNOSTICS LIMITED	224
SQI DIAGNOSTICS	224
SYNAGEVA BIOPHARMA	225
T2 BIOSYSTEMS	225
TALKING20 INC.	226
<i>TABLE 80 PERSONALIZED PROTEOMICS COMPANIES</i>	226
THERANOSTICS HEALTH	227
THERMO FISHER SCIENTIFIC INC.	227
THORNE DIAGNOSTICS INC.	229
TOSOH CORP.	229
UNIVERSAL BIOSENSORS LTD.	229
<i>TABLE 81 UNIVERSAL BIOSENSORS DIAGNOSTIC PIPELINE</i>	230
VERMILLION INC.	231
VG LIFE SCIENCES INC.	232
WATERS CORP.	232
XENCOR INC.	233
YMC CO. LTD.	234
ZEPHYRUS BIOSCIENCES INC.	234

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 ARRAY VERSUS LOAC BIOCHIPS	12
TABLE 2 SCOPE OF REPORT	13
TABLE 3 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	14
TABLE 4 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES	15
TABLE 5 BIOCHIP INDUSTRY COMPARISONS	16
TABLE 6 MASS SPECTROMETER PLATFORMS	23
TABLE 7 BIOCHIP-BASED PROTEOMIC TECHNOLOGIES	23
TABLE 8 PLANAR-BASED VERSUS BEAD-BASED ARRAYS	24
TABLE 9 ADVANTAGES OF MULTIPLEXING FOR DIAGNOSTICS	25
TABLE 10 TECHNICAL ADVANCES IN PROTEOMICS	28
TABLE 11 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	31
TABLE 12 LARGE-SCALE PROTEOMIC INITIATIVES	36
TABLE 13 STRATEGIES FOR OVERCOMING HIGH-ABUNDANCE PROTEINS IN CLINICAL SAMPLES	41
TABLE 14 ESTIMATED U.S. INCIDENCE AND DEATHS FOR SELECTED CANCERS, 2010 AND 2013	42
TABLE 15 STATUS OF BLADDER CANCER NEXT GENERATION DIAGNOSTICS TESTS	43
TABLE 16 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION	46
TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS	47
TABLE 18 STATUS OF NEXT GENERATION BREAST CANCER TESTS	48
TABLE 19 STATUS OF GASTRIC/STOMACH CANCER NEXT GENERATION DIAGNOSTICS TESTS	57
TABLE 20 STATUS OF KIDNEY CANCER NEXT GENERATION DIAGNOSTICS TESTS	58
TABLE 21 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%)	59
TABLE 22 STATUS OF LUNG CANCER NEXT GENERATION DIAGNOSTICS TESTS	60
TABLE 23 STATUS OF LYMPHOMA CANCER NEXT GENERATION DIAGNOSTICS TESTS	63
TABLE 24 EARLY SCREENING OVARIAN CANCER TESTS	64
TABLE 25 STATUS OF OVARIAN CANCER NEXT GENERATION DIAGNOSTICS TESTS	66
TABLE 26 STATUS OF PAN-CANCER NEXT GENERATION DIAGNOSTICS TESTS	68
TABLE 27 STATUS OF PROSTATE CANCER NEXT GENERATION DIAGNOSTICS TESTS	72
TABLE 28 STATUS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS	75
TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES	78
TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET	82
TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS	83
TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014	86
TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014	89
TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS	100
TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES	101
TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES	103
TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES	104
TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES	105
TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY	106
TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES	108

TABLE HEADING	PAGE NO.
TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES	109
TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES	110
TABLE 43 CHINA'S BIOCHIP INDUSTRY	112
TABLE 44 LOAC COMPETITOR LANDSCAPE	114
TABLE 45 ANTIBODY REAGENT MARKET, 2014 (%)	117
TABLE 46 MULTIPLEX PROTEIN IN-VITRO DIAGNOSTICS COMPANIES	118
TABLE 47 DRIED BLOOD SPOT PROTEOMICS INDUSTRY	121
TABLE 48 SINGLE CELL PROTEOMICS INDUSTRY	122
TABLE 49 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES	125
TABLE 50 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2019 (\$ MILLIONS)	127
TABLE 51 GLOBAL PROTEOMIC RESEARCH MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	129
TABLE 52 GLOBAL PROTEOMIC RESEARCH MARKET BY BIOCHIP PLATFORM, THROUGH 2019 (\$ MILLIONS)	130
TABLE 53 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT PRODUCT MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	130
TABLE 54 GLOBAL PROTEOMIC BIOCHIP DRUG DISCOVERY AND DEVELOPMENT MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	131
TABLE 55 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	132
TABLE 56 GLOBAL BIOCHIP DIAGNOSTIC MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	133
TABLE 57 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY DISEASE TYPE, THROUGH 2019 (\$ MILLIONS)	135
TABLE 58 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR DIABETES, NEUROLOGICAL, AUTOIMMUNE, INFECTIOUS DISEASE, HLA TYPING, AND CARDIOVASCULAR DISEASE APPLICATIONS	136
TABLE 59 SEPSIS DIAGNOSTICS INDUSTRY	137
TABLE 60 GLOBAL PROTEOMIC CANCER DIAGNOSTIC PRODUCT MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	139
TABLE 61 GLOBAL MASS SPECTROMETRY MARKET BY PRODUCT TYPE, THROUGH 2019 (\$ MILLIONS)	142
TABLE 62 GLOBAL MASS SPECTROMETRY MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	143
TABLE 63 MRM-MS VERSUS MALDI MS IN CLINICAL APPLICATIONS	145
TABLE 64 MS CLINICAL INDUSTRY	146
TABLE 65 PHOSPHOPROTEOMICS PLATFORMS FOR CANCER APPLICATIONS	148
TABLE 66 GLOBAL MASS SPECTROMETRY INSTRUMENT PROTEOMICS MARKET BY TECHNIQUE, THROUGH 2019 (\$ MILLIONS)	149
TABLE 67 GLOBAL MASS SPECTROMETRY CONSUMABLE MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	150
TABLE 68 GLOBAL PROTEOMIC BIOCHIP MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	151
TABLE 69 GLOBAL PROTEOMIC ARRAY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	152
TABLE 70 GLOBAL PROTEOMIC BIOCHIP MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	153
TABLE 71 GLOBAL PROTEOMIC ARRAY MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	154

TABLE HEADING	PAGE NO.
TABLE 72 GLOBAL PROTEOMIC LOAC MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	156
TABLE 73 GLOBAL PROTEOMIC MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	158
TABLE 74 GLOBAL PROTEOMIC DIAGNOSTIC MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	159
TABLE 75 ARRAY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014	162
TABLE 76 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014	163
TABLE 77 MASS SPECTROMETRY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014 (NO. OF PATENTS)	164
TABLE 78 APPLICATIONS FOR Y2H AND YCHEMH PROTEOMICS PLATFORMS	192
TABLE 79 SOMALOGIC PROTEOMIC METHODS	223
TABLE 80 PERSONALIZED PROTEOMICS COMPANIES	226
TABLE 81 UNIVERSAL BIOSENSORS DIAGNOSTIC PIPELINE	230

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY, 2013-2019 (\$ MILLIONS)	7
FIGURE 1 MASS SPECTROMETRY GENERALIZED WORKFLOW SCHEMATIC	18
FIGURE 2 PROTEOMIC BIOCHIP AND ARRAY FORMATS	19
FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW	104